These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20047144)

  • 1. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
    Richard DJ; Verheijen JC; Zask A
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):428-40. PubMed ID: 20597028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
    Ji J; Zheng PS
    Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
    Sharp ZD; Strong R
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
    [No Abstract]   [Full Text] [Related]  

  • 5. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino acid sensitive TOR pathway from yeast to mammals.
    Dann SG; Thomas G
    FEBS Lett; 2006 May; 580(12):2821-9. PubMed ID: 16684541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An expanding role for mTOR in cancer.
    Guertin DA; Sabatini DM
    Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale for mTOR inhibition in epithelial ovarian cancer.
    Trinh XB; van Dam PA; Dirix LY; Vermeulen PB; Tjalma WA
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1885-91. PubMed ID: 19888868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin: the cure for all that ails.
    Hasty P
    J Mol Cell Biol; 2010 Feb; 2(1):17-9. PubMed ID: 19805415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin: a new target in prostate cancer.
    Rai JS; Henley MJ; Ratan HL
    Urol Oncol; 2010; 28(2):134-8. PubMed ID: 19523861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucosamine induces autophagy via an mTOR-independent pathway.
    Shintani T; Yamazaki F; Katoh T; Umekawa M; Matahira Y; Hori S; Kakizuka A; Totani K; Yamamoto K; Ashida H
    Biochem Biophys Res Commun; 2010 Jan; 391(4):1775-9. PubMed ID: 20045674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth.
    Yang X; Yang C; Farberman A; Rideout TC; de Lange CF; France J; Fan MZ
    J Anim Sci; 2008 Apr; 86(14 Suppl):E36-50. PubMed ID: 17998426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?
    Di Paolo S; Teutonico A; Leogrande D; Capobianco C; Schena PF
    J Am Soc Nephrol; 2006 Aug; 17(8):2236-44. PubMed ID: 16807405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.
    Chapuis N; Tamburini J; Green AS; Willems L; Bardet V; Park S; Lacombe C; Mayeux P; Bouscary D
    Leukemia; 2010 Oct; 24(10):1686-99. PubMed ID: 20703258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.